Variables | Overall survival | Disease-free survival | ||||||
---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
HR(95%CI) | P | HR(95%CI) | P | HR(95%CI) | P | HR(95%CI) | P | |
Gender: male/female | 0.72 (0.19–2.71) | 0.625 | 0.99 (0.37–2.71) | 0.998 | ||||
Age | 1.01 (0.95–1.06) | 0.811 | 0.99 (0.96–1.03) | 0.767 | ||||
Preoperative treatment | 2.73 (0.56–13.34) | 0.214 | 1.78 (0.65–4.94) | 0.265 | ||||
Preoperative CEA level | 0.99 (0.93–1.05) | 0.705 | 1.01 (1.00–1.02) | 0.181 | ||||
Preoperative CA19-9 level | 1.00 (0.99–1.01) | 0.858 | 1.00 (0.99–1.01) | 0.677 | ||||
Histology | 0.89 (0.22–3.64) | 0.870 | 1.00 (0.36–2.78) | 0.999 | ||||
Perineural invasion | 3.89 (0.34–18.10) | 0.083 | 2.03 (0.70–5.90) | 0.195 | ||||
Vascular invasion | 1.06 (0.28–3.99) | 0.935 | 0.77 (0.28–2.14) | 0.612 | ||||
Lymphatic invasion | 6.64 (1.35–32.78) | 0.020 | 2.74 (0.44–17.15) | 0.280 | 3.03 (1.01–9.10) | 0.048 | 1.65 (0.45–5.99) | 0.447 |
T stage: T3-4/T1-2 | 1.17 (0.15–9.42) | 0.884 | 0.50 (0.14–1.80) | 0.289 | ||||
N stage | ||||||||
N0 | Reference | Reference | ||||||
N1 | 0.17 (0.15–1.85) | 0.145 | 0.62 (0.15–2.63) | 0.517 | ||||
N2 | 1.83(0.35–9.68) | 0.477 | 1.38 (0.34–5.57) | 0.654 | ||||
Mesorectal LN harvested | 0.98 (0.91–1.06) | 0.638 | 1.00 (0.94–1.06) | 0.994 | ||||
LPN harvested | 1.01 (0.95–1.08) | 0.742 | 0.98 (0.92–1.05) | 0.605 | ||||
Adjuvant chemotherapy | 0.69 (0.17–2.77) | 0.598 | 0.39 (0.14–1.08) | 0.071 | ||||
Anastomosis leakage or SSI | 1.72 (0.26–11.53) | 0.547 | 1.42 (0.45–3.93) | 0.342 | ||||
High risk LPNM | 15.33 (1.77–133.46) | 0.013 | 9.23 ( 1.46–87.35) | 0.032 | 4.46 (1.38–14.46) | 0.013 | 4.39 (1.33–13.16) | 0.041 |